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sedation for endoscopic procedures that compared outcomes using pulse oxime-
try alone with pulse oximetry plus capnography. Adverse events (AEs) considered 
included apnea, bradycardia, desaturation, and hypotension. Interventions to treat 
AEs were taken from guidelines with costs derived from the Premier database and lit-
erature review. Adverse outcomes included unplanned admission and mortality. Odds 
ratio for events with capnography were taken from RCTs and a meta-analysis, where 
available, data specific to moderate sedation were used. The model base case assumed 
no progression into deep sedation and patients with mean characteristics of age 55 
years, body mass index 26 kg/m2, and 45% male. Probabilistic sensitivity analyses 
were performed. Results: In the base case, utilization of capnography reduced the 
proportion of patients experiencing ≥ 1 AE by 18.0% and resulted in 1 AE of any severity 
being avoided every 9 procedures. The mean number needed to treat (95% credible 
interval [CrI]) to avoid an apnea or severe desaturation AE was 27 (−109–409) and 17 
(4–308), respectively. Due to the reduction in AEs, capnography resulted in a saving 
of $55 (95% CrI −96–247) per procedure at 1 year. The key cost driver was reduced use 
of airway interventions with capnography. Assuming that AEs did not incur costs; 
capnography increased the cost per procedure by $9, costing $83 per adverse event 
avoided. ConClusions: Capnography is likely to be cost-effective for monitoring 
moderate sedation even without considering progression to deep sedation. Estimates 
indicate that it may also be cost saving.
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objeCtives: To conduct a cost-effectiveness analysis (CEA) of capsule endos-
copy (CE) used in the indication of diagnosing small bowel Crohn’s disease 
(CD). Methods: A cost-effectiveness analysis was conducted for a one-year time 
horizon, from third-party–payer perspective only including the direct healthcare 
costs, like outpatient care, inpatient care and pharmaceutical consumption. A deci-
sion tree structure was defined with two alternatives: (1) capsule endoscopy (with 
using patency capsule), (2) standard diagnostic package including Calprotectin test, 
ultrasound, colonoscopy with ileoscopy, CT enterography. The costs are expressed 
in monetary value, the effectiveness is measured as the number of patients with 
accurate and appropriate diagnosis (true negative and true positive). The sensitivity 
and specificity for diagnosing CD used as input data of model are based on a review 
of literature. The value of prevalence of CD and the costing estimates are based on 
Hungarian data. Results: To the available sensitivity, specificity for diagnosing 
CD and the prevalence data, the diagnostic accuracy of CE and standard diagnostic 
package used in Hungary are the followings, respectively: true positive (0.7 vs. 0.532), 
true negative (0.273 vs. 0.2518), false negative (0 vs. 0.168), false positive (0.027 vs. 
0.0482). 97 of 100 patients likely to be diagnosed accurately and appropriately using 
CE compared with 78 of 100 patients using standard diagnostic package. As a result 
of CEA, the ICER value is 703,500 HUF per accurately and appropriately diagnosed 
patient. ConClusions: The CE has been used for years in Hungary in given indica-
tions but not in diagnosing small bowel CD. The ICER calculated is lower than the 
threshold of cost-effectiveness set in Hungary. Taken into account the diagnostic 
yield and the advantages of CE, the result of CEA, extending the indications of CE 
for diagnosing small bowel CD should be considered by the Hungarian health policy.
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objeCtives: To evaluate the cost-effectiveness of an imaging diagnostic strategy for 
stable coronary artery disease (CAD) guided by a new model to estimate the pre-test 
likelihood of disease that integrates specific circulating biomarkers with common 
clinical variables using data collected through the EVINCI study. Methods: In the 
clinical standard path (CSP) pre-test likelihood of disease was estimated by the 
Genders model (based on age, sex and symptoms) while the new clinical-biohumoral 
path (CBP) included the integration of previously selected bio-humoral predictors 
of CAD (HDL-cholesterol, aspartate-transaminase and C-reactive protein) to define 
the pre-test likelihood. In both paths, according to the 2013 ESC-Guidelines for 
management of stable CAD, the pre-test likelihood guided further examinations: 
no other test for low probability (< 15%), non-invasive imaging in intermediate prob-
ability (15%-85%) and direct invasive coronary angiography (ICA) for high probability 
(> 85%). Effectiveness was defined in terms of correct diagnosis at ICA. Costs of the 
diagnostic pathways were calculated per-patients considering reimbursement of 
non-invasive and invasive examinations as well as biomarkers assay in the CBP. All 
costs were expressed in Euro 2013. Results: Considering 487 subjects enrolled in 
the EVINCI study because of suspected CAD and having a complete clinical, bio-
humoral and imaging profile, the CBP dominates the CSP being more effective and 
less costly. Specifically, CBP allowed for 90.6% (±29.3%) correct diagnoses with a 
mean cost of 352.9 Euros (±752.5), while CSP correctly diagnosed 88.9% (±29.3%) of 
cases at a mean cost of 615.6 Euros (±861.1). Results did not change when accounting 
for missed CAD diagnoses. ConClusions: The estimation of pre-test likelihood 
of CAD integrating circulating biomarkers and clinical variables allows for more 
accurate and more cost-effective diagnostic strategies, avoiding unnecessary diag-
nostic tests. The new predictive model is an effective gate-keeper to non-invasive 
and invasive imaging tests in patients with symptoms of stable CAD.
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from the perspective of the NHS in England and Wales. Results were expressed 
in terms of accrued costs and consequences, and one-way sensitivity analysis 
(OWSA) and scenario analysis was used to explore key model assumptions and 
inputs. Results: COPAL® G+C was associated with a reduction in the probability 
of a patient suffering either a deep or superficial infection as well as a reduction 
in the probability of experiencing a revision procedure. Overall, cost savings of 
£1,047.73 per patient were achieved with the use of the dual-antibiotic cement. 
OWSA found results to be robust to changes in key model parameters; assump-
tions around probabilities of 30-day survival were a key model driver. Of explored 
scenarios, the greatest impact was observed with the removal of deep SSIs from the 
model, which reduced cost savings to £93.80 per patient. ConClusions: Use of 
dual antibiotic bone cement can lead to reductions in the rate of SSIs and require-
ments for revision surgery. In addition to a clinical benefit, this has the potential to 
generate meaningful cost savings for the NHS in England and Wales.
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objeCtives: A number of studies have reported that up to 27% of adenomas are 
missed during screening colonoscopy for the prevention or detection of colorectal 
cancer (CRC). A suboptimal adenoma detection rate (ADR) is significantly associated 
with a higher incidence of CRC, with adenomas often being located at the proxi-
mal side of a mucosal fold. ENDOCUFF VISION™ is a novel device that sits firmly 
over the tip of the colonoscope, and which, by flattening mucosal folds, has been 
shown to significantly improve ADR. The benefit of using this device in reducing 
interval CRC has been investigated in a cost-consequence model with a 10 year 
time horizon. Methods: The model compares the use of 2L polyethylene glycol 
+ ascorbate components (2LPEG+ASC) as a bowel cleansing preparation, with or 
without use of this device. The additional cost of the device (set at € 30) is modelled, 
together with the potential cost savings through improved ADR and CRC preven-
tion. Model inputs include rates of successful bowel cleansing, number of com-
pleted colonoscopies, ADR, rates of surveillance colonoscopy, associated costs, and 
resource utilisation in a cohort of 10,000 patients who are eligible for screening in 
the German healthcare system. Model outputs include cases of CRC missed or pre-
vented, cost of colonoscopy, and the per person costs. Results: The model shows 
that the improved ADR through the use of this colonoscope device with 2LPEG+ASC, 
compared with 2LPEG+ASC alone, avoids progression to CRC in more individuals. 
Despite an increase in the overall cost due to repeat colonoscopies, the use of the 
device leads to an overall saving in CRC treatment costs of € 5,137,894, resulting in 
a cost saving of € 283 per person screened over 10 years. ConClusions: The use 
of ENDOCUFF VISION™ can improve ADR, which may reduce the development of 
CRC, avoid treatment costs, and reduce mortality.
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objeCtives: To conduct a cost-effectiveness analysis (CEA) of continuous remote 
monitoring (RM) of heart failure (HF) patients with cardiac electronic implantable 
device. Methods: A cost-effectiveness analysis was conducted for a 10-year time 
horizon, from third-party–payer perspective only including the direct healthcare 
costs. A Markov model was adapted with four health states for two alternatives: 
(1) continuous RM with data transmission on a daily basis, (2) conventional, regu-
lar in-office follow-up (CFU). The costing estimates are based on Hungarian data. 
The effectiveness is measured as the number of life years saved. The input data 
of effectiveness are based on randomised clinical trials and data provision of the 
Hungarian National Health Insurance Fund Administration. Results: As a result 
of CEA, 652 life years can be saved in a 10-year time horizon in a patient cohort 
(N= 100). The ICER value is 1.78 million HUF (≈ 5,730 EUR) per life year saved. To our 
estimation 4,500-5,600 HF patients could be continuously remote monitored by 
the end of the 5th year with a gradual inclusion of patients. Taking into account 
the mortality of both arms, under 5 years, extra 520-650 lives (among the gradually 
involved 4,500-5,600 patients) can be saved with using RM compared to the CFU. 
Both to the deterministic and probabilistic sensitivity analysis the ICER calculated 
is relatively robust. ConClusions: The ICER calculated is lower than the thresh-
old of cost-effectiveness set in Hungary. The number of lives can be potentially 
saved is favourable, especially by the HF patient population regarding its relatively 
low 5-year survival rate (below 50%). The Hungarian health policy should consider 
the inclusion of RM into the public reimbursement system and at the same time 
establishing a patient registry for the remotely monitored HF patients to evaluate 
the long term benefits of RM.
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objeCtives: Capnography monitoring is recommended during moderate sedation, 
although its uptake has been restricted by concerns over excess costs and demonstra-
tion of safety benefit. This analysis investigates the cost-effectiveness of capnography 
for moderate sedation during gastrointestinal endoscopy. Methods: Randomized 
clinical trial (RCT) and large-scale study data were used to build a model of moderate 
